First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
Research To Practice | Oncology Videos · Dr. Neil Love
April 10, 202557m 29s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Justin F Gainor, including the following topics:
- Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)
- Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38)
- Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32)
- Tolerability profile of lorlatinib (23:28)
- Review of clinical investigator survey results (37:08)
- Novel ALK inhibitors under clinical development (53:22)